Shuang Xiang

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance

Zuqin Wang, Jie Wang, Yongjin Wang et al. · Journal of Medicinal Chemistry · 2022 · 36 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Shuang Xiang, Xiaoyun Lu · Acta Pharmaceutica Sinica B · 2023 · 29 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Discovery +1

Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies

Jing Guo, Shuang Xiang, Jie Wang et al. · European Journal of Medicinal Chemistry · 2021 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy

Shuang Xiang, Jie Wang, Huisi Huang et al. · European Journal of Medicinal Chemistry · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +15

<scp>SAR1A</scp> regulates the <scp>RhoA</scp>/<scp>YAP</scp> and autophagy signaling pathways to influence osteosarcoma invasion and metastasis

Fangbiao Zhan, Qianrong Deng, Zhiyu Chen et al. · Cancer Science · 2022 · 14 citations · Full text

Medicine, Cancer Biology, Oncology +17